Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
NAT2 encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Zusätzlich bieten wir Ihnen NAT2 Proteine (9) und NAT2 Kits (1) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 63 products:
Human Polyclonal NAT2 Primary Antibody für WB - ABIN2781757
Ricco, Cau, Marchand, Marty, Rodde-Dunet, Fender, Allemand, Corsini: Stent-graft repair for thoracic aortic disease: results of an independent nationwide study in France from 1999 to 2001. in The Journal of thoracic and cardiovascular surgery 2006
The increased risk of prostate cancer was observed among individuals with the NAT2 (zeige SLC38A1 Antikörper) slow acetylator phenotype
Genotyping of TB patients from south India for NAT2 gene polymorphism revealed that 58 per cent of the study population comprised slow acetylators. Two-hour INH concentrations differed significantly among the three genotypes.
Slow NAT2 (zeige SLC38A1 Antikörper) acetylators demonstrated a significant association with risk of anti-tuberculosis drug-induced liver injury in Thai patients.
The present study demonstrated no association between NAT2 (zeige SLC38A1 Antikörper) genotype and drug-induced hepatotoxicity in the north Indian patients with tuberculosis.
CYP3A4 (zeige CYP3A4 Antikörper) expression and N-acetyl transferase 2 acetylator phenotype can better identify the patients with higher risk of adverse reactions and can facilitate the improvement of personalized clonazepam therapy and withdrawal regimen.
NAT2 (zeige SLC38A1 Antikörper) genotypes are associated with N-acetylation phenotype variation.
NAT2 (zeige SLC38A1 Antikörper) acetylator genotype has an important role in 4, 4'-methylene bis (zeige BAG3 Antikörper) (2-chloroaniline) metabolism and suggest that risk assessments related to 4, 4'-methylene bis (zeige BAG3 Antikörper) (2-chloroaniline) exposures consider accounting for NAT2 (zeige SLC38A1 Antikörper) acetylator phenotype in the analysis
Review/Meta-analysis: NAT2 (zeige SLC38A1 Antikörper) slow acetylation genotype is associated with an increased bladder cancer risk in Chinese individuals.
six selected NAT2 (zeige SLC38A1 Antikörper) exonic single nucleotide polymorphisms were genotyped in an independent case-control sample of a Northern Chinese Han population to verify the possible association between NAT2 (zeige SLC38A1 Antikörper) and schizophrenia. Three (rs1801280T/341C, rs1799930/G590A, and rs1208/A803G) of the six single nucleotide polymorphisms showed significant allele frequency differences between the case and the control groups.
Our findings suggested that NAT2 (zeige SLC38A1 Antikörper) gene polymorphism rs1799931 was associated with decreased risk of acute myeloid leukemia (zeige BCL11A Antikörper) and was likely to be a protective factor against acute myeloid leukemia (zeige BCL11A Antikörper) development.
This study illustrated that deficiency of NAT1/2 decreases isoniazid (INH) acetylation, but increases the interactions of INH with endobiotics in the liver.
It was concluded that an acute colonic inflammation impairs the expression and function of NAT2 enzyme, thereby diminishing the capacity for 5-aminosalisylic acid metabolism by colonic mucosa.
Hyperhomocysteinemia-induced decrease of peroxynitrite level is associated with an increase of hepatic Nat2 isoform activity with a reversal effect of wine polyphenol extract supplementation.
Mouse NAT2 is likely to influence epigenetic gene control, particularly of its own locus, and this is consistent with recent evidence associating aberrant mouse Nat2/human NAT1 (zeige EIF4G2 Antikörper) gene expression with certain developmental malformations and cancers.
Nat2 knockout mouse line demonstrates that different Nat2 isoforms have distinct functions with no compensatory expression, in Nat2 knockout animals, of the other isoforms.
Variation in capacity for acetylation of 4ABP and PABA resulting from endogenous murine NAT2 alleles is insufficient to affect 4ABP genotoxicity in liver.
Results suggest that peroxynitrite-dependent inactivation of NAT1 (zeige EIF4G2 Antikörper) and 2 may contribute to muscle dysfunction by impairing the biotransformation activity of this key cellular defense enzyme system.
These ocular phenotypes and their association with Nat2 genotype indicate that the Nat2 locus may be responsible for the previously described microphthalmic Cat4 (zeige SLC7A4 Antikörper) phenotype.
study reports the detailed expression of the Nat2 gene and encoded protein in mouse embryos
Mouse N-acetyltransferase-2 was produced as a recombinant protein and found to have a substrate specificity profile similar to human N-acetyltransferase type 1 (zeige NAT1 Antikörper).
The study is the first to thoroughly characterize the properties of a polymorphic NAT isoenzyme in a non-human primate model.
This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2).
N-acetyltransferase type 2
, arylamide acetylase 2
, arylamine N-acetyltransferase 2
, lambda R-1
, polymorphic arylamine N-acetyltransferase
, N-acetyl transferase 2
, N-Acetyltransferase-2 (arylamine N-acetyltransferase)
, N-acetyltransferase 2 (arylamine N-acetyltransferase)
, Arylamide acetylase 2
, NAT2 15
, Polymorphic arylamine N-acetyltransferase
, arylamine N-acetyltransferase-2